Table 1.
Post hoc contrasts for Phase 1 ANOVAs conducted separately for each concurrent schedule (a) or component (b) for lean and obese rats, with pellet type (CAR/CAR vs. SUC/SUC) as a between-subjects factor, and dose of rimonabant as a within-subjects factor. Significant contrasts are shown, which correspond to Figure 1 (a) and Figure 2 (b). Pellet type is omitted, as it was not found to be a significant factor in any analysis.
| (a) Fig 1. Reinforcers by schedule | ||||||
|---|---|---|---|---|---|---|
| Programmed ratio | Dose compared to vehicle | F | df | p | ηp2 | |
|
|
||||||
| Lean | 5:1 schedule | 10.0 mg/kg | 12.7 | (1,8) | 0.008 | 0.61 |
|
| ||||||
| 1:5 schedule | 3.0 mg/kg | 5.88 | (1,8) | 0.042 | 0.42 | |
| 10.0 mg/kg | 16.34 | (1,8) | 0.004 | 0.67 | ||
| Obese | 5:1 schedule | 10.0 mg/kg | 19.23 | (1,8) | 0.002 | 0.71 |
|
| ||||||
| 1:5 schedule | 10.0 mg/kg | 78.53 | (1,8) | < 0.001 | 0.91 | |
| (b) Fig 2. Reinforcers by component | ||||||
|---|---|---|---|---|---|---|
| Programmed component | Dose compared to vehicle | F | df | p | ηp2 | |
|
|
||||||
| Lean | VI 12-s | 10.0 mg/kg | 13.84 | (1,8) | 0.006 | 0.63 |
|
| ||||||
| VI 60-s | 10.0 mg/kg | 17.56 | (1,8) | 0.003 | 0.69 | |
| Obese | VI 12-s | 10.0 mg/kg | 75.2 | (1,8) | < 0.001 | 0.9 |
|
| ||||||
| VI 60-s | 10.0 mg/kg | 71.27 | (1,8) | < 0.001 | 0.9 | |